Latest Headlines

Latest Headlines

China's Sinocare interested in buying Bayer diabetes device unit

Chinese bidders are emerging in the long-sought sale of Bayer's diabetes device business, as the German giant seeks to focus on its core pharmaceutical interests.

Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go

Perrigo's not opposed to striking a pact with Mylan--as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close.

Heavyweight investors sock big bucks into Valeant while others sell down

Valeant's former deal partner Bill Ackman is pretty rosy on his outlook for the company, as he's shown with a large share-grab and comparison to Warren Buffett's Berkshire Hathaway. But he's not the only one.

Endo scoops up Par Pharma for $8B to gain ground in injectables

After Endo lost Salix earlier this year, analysts didn't think there would be much left for the drugmaker in terms of M&A. But now, the company is snatching up generics maker Par Pharmaceutical for $8 billion, getting its hands on the company's generic drug portfolio to expand its offerings and generate long-term growth.

Cortendo splashes $35M on a pair of acromegaly drugs

Swedish-American biotech Cortendo is expanding its focus on rare endocrine diseases, buying a pair of Phase II treatments for acromegaly for a combined $35 million.

Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M

Clinical stage allergy player Circassia Pharmaceuticals, which had a huge $332 million IPO on the London Stock Exchange last year, will scoop up Swedish asthma company Aerocrine for SEK 1.78 billion ($214.3 million) after it got its latest asthma diagnostic device cleared by FDA in November.

Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line

NantWorks, the nebulous empire of biotech billionaire Patrick Soon-Shiong, is handing over $90 million to partner Sorrento Therapeutics in exchange for a Phase III cancer drug heralded as a successor to the blockbuster Abraxane.

Circassia snags a pair of asthma biotechs for $371M

Circassia, the U.K. biotech that pulled off a major IPO last year, spent a combined $371 million on two asthma-focused drug developers in an effort to expand its pipeline beyond its home turf of allergy immunotherapies.

Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds

Last year, Mylan forked over millions to cover its top execs' tax liability on its deal with Abbott Laboratories, which shifted its tax domicile to Europe. Investors weren't so lucky--and now, they may take another tax hit if Mylan joins up with suitor Teva.

Physician services player Mednax buys into teleradiology with $500M vRad acquisition

Mednax has built its $6.7 billion business by providing specialized, outsourced services to hospitals for everything from neonatal, anesthesia, maternal-fetal to pediatric physician subspecialties. Now it's added teleradiology to that mix with the purchase of Virtual Radiologic (vRad) for $500 million in cash.